Compare Google Inc (GOOG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Google IncTrade

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Google Inc vs Neurocrine Biosciences Inc — how do they compare? Google Inc trades at $343.43 (market cap $4.20T), while Neurocrine Biosciences Inc trades at $155.49 (market cap $16.46B). The key difference: Google Inc is far larger — about 255.2× Neurocrine Biosciences Inc's market cap, and Google Inc pays a 0.26% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

	GOOG	NBIX
Market Cap	$4.20T	$16.46B
Volume	1,511,127	—
Sector	Technology	Health
52-Week High	$399.06	$185.50
52-Week Low	$200.19	$123.10
Enterprise Value	$4.09T	$16.48B
Dividend Yield	0.26%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Google Inc

Alphabet (GOOG) trades at $355.84, up 0.67% on the day, with a bullish technical signal from moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $402.84 billion in 2025, with net income surging to $132.17 billion, and announced a new AI leadership structure to accelerate Gemini development amid rising user adoption.

Outlook remains positive with an 86.84% analyst buy rating and a $431.67 consensus price target, though risks include high capital expenditure for AI infrastructure and regulatory scrutiny. The stock offers growth potential from AI monetization but faces volatility from tech sector pressures and antitrust investigations.

Neurocrine Biosciences Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GOOG

Oil prices rise amid geopolitical tensions; AI tech stocks face growing investor scrutiny and risks.Seeking Alpha · 1 day agoNeutral Meta and Alphabet Q2 results highlight diverging AI investment impacts on margins and growth.24/7 Wall Street · 3 days agoNeutral Berkshire Hathaway ends 14-quarter stock selling streak, starts buying again with $20B net purchases.24/7 Wall Street · 4 days agoBullish View details →

NBIX

INGREZZA shows significant quality of life and movement improvements in tardive dyskinesia patients after 24 weeks.PRNewsWire · 5 hours agoBullish View details →

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.